5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Direct reversal of glucocorticoid resistance by AKT inhibition in acute lymphoblastic leukemia.

      Cancer Cell
      Active Transport, Cell Nucleus, Animals, Dexamethasone, therapeutic use, Drug Resistance, Neoplasm, Heterocyclic Compounds, 3-Ring, pharmacology, Humans, Mice, PTEN Phosphohydrolase, physiology, Phosphorylation, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, drug therapy, Proto-Oncogene Proteins c-akt, antagonists & inhibitors, Receptors, Glucocorticoid, metabolism

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Glucocorticoid resistance is a major driver of therapeutic failure in T cell acute lymphoblastic leukemia (T-ALL). Here, we identify the AKT1 kinase as a major negative regulator of the NR3C1 glucocorticoid receptor protein activity driving glucocorticoid resistance in T-ALL. Mechanistically, AKT1 impairs glucocorticoid-induced gene expression by direct phosphorylation of NR3C1 at position S134 and blocking glucocorticoid-induced NR3C1 translocation to the nucleus. Moreover, we demonstrate that loss of PTEN and consequent AKT1 activation can effectively block glucocorticoid-induced apoptosis and induce resistance to glucocorticoid therapy. Conversely, pharmacologic inhibition of AKT with MK2206 effectively restores glucocorticoid-induced NR3C1 translocation to the nucleus, increases the response of T-ALL cells to glucocorticoid therapy, and effectively reverses glucocorticoid resistance in vitro and in vivo. Copyright © 2013 Elsevier Inc. All rights reserved.

          Related collections

          Author and article information

          Comments

          Comment on this article